RE:RE:RE:RE:Where's the news on TH1902? I don't think they said they would inform the market of what the SAC is working on or decides (decided?) on because nothing is really decided until they put a package together to first address the FDA questions arising from 1A portion and then inform them of the new protocol and what data they have to suggest it is a valid way forward, safe, and should improve outcomes. Until you really get all that done, all you can say is we have a crack-bang committee of experts, we compiled all human data, we've analyzed and reviewed it all to draw conclusions on both next steps and answers to all and any FDA issue around the past trial and a new protocol. And they've basically said that already. They shouldn't, nor won't, tell us details from the SAC analysis. We may hear things like "constructive dialog around data"..."..data supports way forward with adjusted parameters..." etc... That kind of top level more vague show that it's moving forward.
On the dilution, if the share slowly goes up towards it's $2-3 level, the warrants from the OO may not be exercised in time and only the Marathon ones will. So it could be less dilution. The only way we see all warrants exercised is if the share get's over $3.30-40 or whatever that OO strike was at. In other words, if there's very good news in the short term. I don't think we'd argue with good news both moving the share to that level and having some extra cash to pay down the loan.